Halozyme Therapeutics (HALO) Total Current Liabilities (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Total Current Liabilities data on file, last reported at $363.2 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 141.53% year-over-year to $363.2 million in Q1 2026; TTM through Mar 2026 was $363.2 million, a 141.53% increase from a year earlier, with the FY2025 full-year figure at $177.1 million, up 27.31% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $363.2 million, up from $177.1 million in the prior quarter.
• Over the last five years, Total Current Liabilities for HALO reached as high as $837.2 million in Q3 2025 and fell as low as $91.9 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $186.0 million across 5 years, with a median of $131.6 million in 2024.
• Across the five-year window, Total Current Liabilities tumbled 41.66% in 2023 and jumped 669.4% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $130.8 million in 2022, then decreased by 13.99% to $112.5 million in 2023, then gained by 23.65% to $139.1 million in 2024, then climbed by 27.31% to $177.1 million in 2025, then surged by 105.1% to $363.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $363.2 million in Q1 2026, $177.1 million in Q4 2025, and $837.2 million in Q3 2025.